Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose ...

One new company quietly gaining traction as a must-have in this space is RAD Intel, which leverages AI within a highly ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spero’s SPR729 is a prodrug that converts into an active form that targets ATPase site of DNA gyrase B in mycobacteria. Image credit: Lemonsoup14 / Shutterstock. Spero Therapeutics has suspended the ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...

Gadkari also encouraged small firms with innovative technologies to participate in government tenders, stressing the importance of cost-effectiveness while maintaining profit margins without ...

Extraordinary General Meeting (EGM) scheduled to be held on Friday, 05-July-2024 at 04.00 p.m. MosChip Technologies Outcome Of Circular Resolution - Moschip EGM Rescheduled To Be Held On Friday, ...